טוען...
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog(®); Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus(®))....
שמור ב:
| הוצא לאור ב: | Diabetes Technol Ther |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5771536/ https://ncbi.nlm.nih.gov/pubmed/29355435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2017.0373 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|